Advertisement
The Body: The Complete HIV/AIDS Resource
Follow Us Follow Us on Facebook Follow Us on Twitter Download Our App
Professionals >> Visit The Body PROThe Body en Espanol
  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

Covalent Vaccination and Catalytic Antibodies: A New Way of Looking at an HIV Vaccine

June 2011

 < Prev  |  1  |  2 

Acknowledgments

The authors' research was funded by the National Institutes of Health, University of Texas Houston Medical School, Abzyme Research Foundation and Covalent Bioscience Inc. We thank Dr. Carl Hanson for reading the manuscript and discussions.


Conflict Statement

Sudhir Paul, Stephanie Planque, Miguel Escobar and Yasuhiro Nishiyama have a financial interest in patents covering the covalent immunization and catalytic antibody areas. Sudhir Paul and Richard Massey have a financial interest in Covalent Bioscience Inc. Sudhir Paul is scientific advisor for the company.


Affiliation

* Chemical Immunology Research Center and Gulf States Hemophilia and Thrombophilia Center, Departments of Pathology and Pediatrics, University of Texas-Houston Medical School; † Covalent Bioscience Inc; ‡ Abzyme Research Foundation


References

  1. Taylor BS, Sobieszczyk ME, McCutchan FE, Hammer SM. The challenge of HIV-1 subtype diversity. N Engl J Med 2008,358:1590-1602.
  2. Karlsson Hedestam GB, Fouchier RA, Phogat S, Burton DR, Sodroski J, Wyatt RT. The challenges of eliciting neutralizing antibodies to HIV-1 and to influenza virus. Nat Rev Microbiol 2008,6:143-155.
  3. Goodglick L, Zevit N, Neshat MS, Braun J. Mapping the Ig superantigen-binding site of HIV-1 gp120. J Immunol 1995,155:5151-5159.
  4. Berberian L, Goodglick L, Kipps TJ, Braun J. Immunoglobulin VH3 gene products: natural ligands for HIV gp120. Science 1993,261:1588-1591.
  5. Planque S, Nishiyama Y, Taguchi H, Salas M, Hanson C, Paul S. Catalytic antibodies to HIV: physiological role and potential clinical utility. Autoimmun Rev 2008,7:473-479.
  6. Pitisuttithum P, Gilbert P, Gurwith M, Heyward W, Martin M, van Griensven F, et al. Randomized, double-blind, placebo-controlled efficacy trial of a bivalent recombinant glycoprotein 120 HIV-1 vaccine among injection drug users in Bangkok, Thailand. J Infect Dis 2006,194:1661-1671.
  7. Sekaly RP. The failed HIV Merck vaccine study: a step back or a launching point for future vaccine development? J Exp Med 2008,205:7-12.
  8. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, Kaewkungwal J, Chiu J, Paris R, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N Engl J Med 2009,361:2209-2220.
  9. Haynes BF, Fleming J, St Clair EW, Katinger H, Stiegler G, Kunert R, et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 2005,308:1906-1908.
  10. Zhou T, Xu L, Dey B, Hessell AJ, Van Ryk D, Xiang SH, et al. Structural definition of a conserved neutralization epitope on HIV-1 gp120. Nature 2007,445:732-737.
  11. Saphire EO, Montero M, Menendez A, van Houten NE, Irving MB, Pantophlet R, et al. Structure of a high-affinity "mimotope" peptide bound to HIV-1-neutralizing antibody b12 explains its inability to elicit gp120 cross-reactive antibodies. J Mol Biol 2007,369:696-709.
  12. Karle S, Planque S, Nishiyama Y, Taguchi H, Zhou YX, Salas M, et al. Cross-clade HIV-1 neutralization by an antibody fragment from a lupus phage display library. AIDS 2004,18:329-331.
  13. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, et al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010,24:875-884.
  14. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.
  15. Planque S, Mitsuda, Y, Ghosh, D, Nishiyama, Y, Hanson, C.V, Paul, S, 18-23 August, 2010, Vienna, Austria; Prototype covalent HIV vaccine for inducing antibodies that neutralize genetically divergent virus strains. XVIII International AIDS Conference 2010, Abstract: TUAA0101. Slide presentation available at http://pag.aids2010.org/flash/?pid=100572.
  16. Planque S, Taguchi H, Burr G, Bhatia G, Karle S, Zhou YX, et al. Broadly distributed chemical reactivity of natural antibodies expressed in coordination with specific antigen binding activity. J Biol Chem 2003,278:20436-20443.
  17. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.
  18. Planque S, Mitsuda, Y, Ghosh, D, Nishiyama, Y, Hanson, C.V, Paul, S, 18-23 August, 2010, Vienna, Austria; Prototype covalent HIV vaccine for inducing antibodies that neutralize genetically divergent virus strains. XVIII International AIDS Conference 2010, Abstract: TUAA0101. Slide presentation available at http://pag.aids2010.org/flash/?pid=100572.
  19. Paul S, Karle S, Planque S, Taguchi H, Salas M, Nishiyama Y, et al. Naturally occurring proteolytic antibodies: selective immunoglobulin M-catalyzed hydrolysis of HIV gp120. J Biol Chem 2004,279:39611-39619.
  20. Ibid.
  21. Planque S, Mitsuda Y, Taguchi H, Salas M, Morris MK, Nishiyama Y, et al. Characterization of gp120 Hydrolysis by IgA Antibodies from Humans without HIV Infection. AIDS Res Hum Retroviruses 2007,23:1541-1554.
  22. Ibid.
  23. Paul S, Planque S, Zhou YX, Taguchi H, Bhatia G, Karle S, et al. Specific HIV gp120-cleaving antibodies induced by covalently reactive analog of gp120. J Biol Chem 2003,278:20429-20435.
  24. Nishiyama Y, Mitsuda Y, Taguchi H, Planque S, Salas M, Hanson CV, Paul S. Towards covalent vaccination: improved polyclonal HIV neutralizing antibody response induced by an electrophilic gp120 V3 peptide analog. J Biol Chem 2007,282:31250-31256.
  25. Odintsova ES, Kharitonova MA, Baranovskii AG, Sizyakina LP, Buneva VN, Nevinsky GA. Proteolytic activity of IgG antibodies from blood of acquired immunodeficiency syndrome patients. Biochemistry (Mosc) 2006,71:251-261.
  26. Baranova SV, Buneva VN, Kharitonova MA, Sizyakina LP, Calmels C, Andreola ML, et al. HIV-1 integrase-hydrolyzing IgM antibodies from sera of HIV-infected patients. Int Immunol 2010,22:671-680.
  27. Vercruysse T, Pardon E, Vanstreels E, Steyaert J, Daelemans D. An intrabody based on a llama single-domain antibody targeting the N-terminal alpha-helical multimerization domain of HIV-1 rev prevents viral production. J Biol Chem 2010,285:21768-21780.
  28. Savarino A, Mai A, Norelli S, El Daker S, Valente S, Rotili D, et al. "Shock and kill" effects of class I-selective histone deacetylase inhibitors in combination with the glutathione synthesis inhibitor buthionine sulfoximine in cell line models for HIV-1 quiescence. Retrovirology 2009,6:52.
  29. Planque S, Salas M, Mitsuda Y, Sienczyk M, Escobar MA, Mooney JP, et al. Neutralization of genetically diverse HIV-1 strains by IgA antibodies to the gp120-CD4-binding site from long-term survivors of HIV infection. AIDS 2010,24:875-884.
  30. Nishiyama Y, Planque S, Mitsuda Y, Nitti G, Taguchi H, Jin L, et al. Toward effective HIV vaccination: induction of binary epitope reactive antibodies with broad HIV neutralizing activity. J Biol Chem 2009,284:30627-30642.
 < Prev  |  1  |  2 


  
  • Email Email
  • Comments Comments
  • Printable Single-Page Print-Friendly
  • Glossary Glossary
  • PDF PDF

This article was provided by Gay Men's Health Crisis. It is a part of the publication GMHC Treatment Issues. Visit GMHC's website to find out more about their activities, publications and services.
 
See Also
More News and Analysis on Vaccines for HIV Prevention

No comments have been made.
 

Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)

Your Name:


Your Location:

(ex: San Francisco, CA)

Your Comment:

Characters remaining:

Tools
 

Advertisement